US Pharma MarketingTo get drugmakers into ultra-rare disease, the answer isn’t rare disease at all, experts say
Rare disease experts say ultra-rare drug programs need platform tech or multi-disease strategies to draw pharma investment. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
OXFORD, England — Making rare disease treatments economically attractive for drugmakers requires looking outside rare disease, according to experts interviewed by Endpoints News.
The pharmaceutical industry’s lack of investment in ultra-rare diseases came up time ...
Source: Endpoints News